Neurocrine Biosciences Inc

NASDAQ: NBIX
$125.74
+$1.76 (+1.4%)
Closing Price on November 8, 2024

NBIX Stock Chart and Intraday Price

NBIX Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 12780 EL CAMINO REAL, SAN DIEGO, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 13,065.34M USD
Shares Outstanding 99,508,000
Neurocrine Biosciences Inc is a biopharmaceutical company based in San Diego, California, focusing on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio includes INGREZZA for tardive dyskinesia, ALKINDI for adrenal insufficiency, and several products for conditions like Huntington’s disease, endometriosis, and uterine fibroids. The company is also advancing a range of candidates for conditions such as developmental and epileptic encephalopathy, major depressive disorder, and schizophrenia, among others. Neurocrine Biosciences maintains collaborations with various pharmaceutical companies to enhance its research and development efforts.

NBIX Articles

Thursday's top analyst upgrades and downgrades included Best Buy, Carnival, Caterpillar, Centene, ChargePoint, Foot Locker, Hewlett Packard Enterprise, Palo Alto Networks, PDD, Peloton Interactive,...
Thursday's top analyst upgrades and downgrades included Advanced Micro Devices, Caesars Entertainment, Caterpillar, CrowdStrike, Crown Castle, Electronic Arts, Estee Lauder, KeyCorp, Match, Norwegian...
Tuesday's top analyst upgrades and downgrades included American Express, Apple, AppLovin, Conagra Brands, D.R. Horton, Estee Lauder, Juniper Networks, Livent, Microsoft, Netflix, Nvidia, Shopify,...
Friday's top analyst upgrades and downgrades included American Express, Aptiv, BorgWarner, First Horizon, Keurig Dr Pepper, Meta Platforms, MGIC Investment, Simon Property Group and Teva...
Friday's top analyst upgrades and downgrades included Builders FirstSource, CVS Health, DHT, Incyte, McDonald's, Newell Brands, PacWest Bancorp, Wingstop and ZoomInfo Technologies.
Wednesday's top analyst upgrades and downgrades included Annaly Capital Management, Capri, Chegg, Coinbase Global, CrowdStrike, Dell Technologies, Fortinet, HP, Kohl's, Palo Alto Networks, Penn...
Friday's top analyst upgrades and downgrades included American Tower, Charles Schwab, Crown Castle, DiamondRock Hospitality, DraftKings, Enphase Energy, GitLab, Interpublic Group of Companies,...
Monday's top analyst upgrades and downgrades included Bill.com, Boeing, Cardinal Health, Cognizant Technology Solutions, ConocoPhillips, C3.ai, Enphase Energy, Ford, International Paper, Meta...
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, Arista Networks, Biogen, CyberArk Software, Global Payments, Kanzhun, Medical Properties Trust, Meta Platforms, Nvidia...
Tuesday's top analyst upgrades and downgrades included Bristol-Myers Squibb, Costco Wholesale, Dollar General, Exxon Mobil, FedEx, Horizon Therapeutics, Hyatt Hotels, Lucid, Medtronic, Micron...
Monday's top analyst upgrades and downgrades included Adobe, Coinbase Global, Datadog, FedEx, Fortinet, Hertz Global, Infosys, McDonald's, Palo Alto Networks, Roblox, Schlumberger, Teck Resources and...
Tuesday's top analyst upgrades and downgrades included Best Buy, Cigna, Exxon Mobil, Futu, GoodRx, Lululemon Athletica, Merck, Monster Beverage, MP Materials, Nike, Visa and Walmart.
Wednesday's top analyst upgrades and downgrades included Activision Blizzard, Alcoa, Amgen, Bank of New York Mellon, Boston Beer, Charles Schwab, Freeport-McMoRan, Kroger, Live Nation Entertainment,...
Friday's top analyst upgrades and downgrades included Chevron, Citigroup, Costco, Intel, Kinross Gold, Southwest Airlines, Take-Two Interactive Software, Teladoc, Teradyne, Vale and Workhorse.
Friday afternoon's top analyst upgrades and downgrades included BP, Carvana, Iron Mountain, Latch and LivePerson.